Get the Stockscreener App
124.19
0.88%
-1.10
After Hours:
124.19
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $124.19, with a volume of 4.99M.
It is down -0.88% in the last 24 hours and down -1.69% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$125.29
Open:
$124.7
24h Volume:
4.99M
Relative Volume:
0.81
Market Cap:
$215.95B
Revenue:
$43.84B
Net Income/Loss:
$13.90B
P/E Ratio:
15.58
EPS:
7.9725
Net Cash Flow:
$6.92B
1W Performance:
-0.52%
1M Performance:
-1.69%
6M Performance:
-7.40%
1Y Performance:
+9.48%
1-Day Range:
$123.64
$125.25
1-Week Range:
$123.64
$126.24
52-Week Range:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
124.19 | 217.86B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
94.71 | 141.35B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
348.18 | 134.41B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
96.05 | 123.15B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.33 | 49.47B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Synergy Asset Management LLC Sells 40,094 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Acquired by Asset Management One Co. Ltd. - MarketBeat
2 Healthcare Stocks to Buy in a Bear Market - The Globe and Mail
JARISLOWSKY FRASER Ltd Has $289.05 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (NYSE:ABT) Has A Rock Solid Balance Sheet - 富途牛牛
Returns On Capital Are Showing Encouraging Signs At Abbott Laboratories (NYSE:ABT) - simplywall.st
Tectonic Advisors LLC Decreases Stock Holdings in Abbott Laboratories $ABT - MarketBeat
The Truth About Abbott Laboratories: Is This ‘Boring’ Stock Actually a Secret Power Play? - AD HOC NEWS
Top 2 Health Care Stocks That May Crash In Q1 - Benzinga
Allspring Global Investments Holdings LLC Acquires 69,578 Shares of Abbott Laboratories $ABT - MarketBeat
Bank Pictet & Cie Europe AG Has $9.82 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature - FinancialContent
Ninety One SA PTY Ltd Takes $1.49 Million Position in Abbott Laboratories $ABT - MarketBeat
Mather Group LLC. Raises Position in Abbott Laboratories $ABT - MarketBeat
Merit Financial Group LLC Acquires 20,035 Shares of Abbott Laboratories $ABT - MarketBeat
With EPS Growth And More, Abbott Laboratories (NYSE:ABT) Makes An Interesting Case - Yahoo Finance
Abbott Laboratories (ABT): Buy, Sell, or Hold Post Q3 Earnings? - FinancialContent
The Truth About Abbott Laboratories: Viral Hype Or Boring Boomer Stock You’re Sleeping On? - AD HOC NEWS
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock - Yahoo Finance
Shum Financial Group Inc. Acquires Shares of 8,127 Abbott Laboratories $ABT - MarketBeat
VIRGINIA RETIREMENT SYSTEMS ET Al Purchases 245,400 Shares of Abbott Laboratories $ABT - MarketBeat
Brendel Financial Advisors LLC Sells 23,978 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott stock today: ABT rises as Exact Sciences deal filing and Volt AFib device stay in focus - ts2.tech
Abbott (ABT) Wins FDA Approval for Volt PFA System in AFib Treatment - Finviz
Traders Buy Large Volume of Call Options on Abbott Laboratories (NYSE:ABT) - MarketBeat
Exact Sciences Approves Executive Bonus Acceleration Amid Abbott Merger - The Globe and Mail
Oak Harvest Investment Services Decreases Stake in Abbott Laboratories $ABT - MarketBeat
Diversified Trust Co Boosts Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock Walks a Tightrope Between Defensive Haven and Growth Re?Rating - AD HOC NEWS
U.S. Embolic Protection Devices Market and Competition - GlobeNewswire
U.S. Embolic Protection Devices Market and Competition Analysis, 2025-2033, Featuring Abbott Laboratories, Allium Medical Solutions, Boston Scientific, Cardinal Health and More - Yahoo Finance
Ethic Inc. Has $29.96 Million Position in Abbott Laboratories $ABT - MarketBeat
Tealwood Asset Management Inc. Grows Stock Position in Abbott Laboratories $ABT - MarketBeat
Rede Wealth LLC Purchases New Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Pacer Advisors Inc. - MarketBeat
Is AbbVie a Buy, Sell, or Hold in 2026? - The Motley Fool
Is Weakness In Abbott Laboratories (NYSE:ABT) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - Yahoo Finance
Abbott Laboratories $ABT Shares Acquired by Brookstone Capital Management - MarketBeat
What you need to know ahead of Abbott Laboratories' earnings release - MSN
V. M. Manning & CO. Inc. Makes New $2.70 Million Investment in Abbott Laboratories $ABT - MarketBeat
What You Need to Know Ahead of Abbott Laboratories' Earnings Release - Yahoo Finance
Abbott Laboratories Pakistan : Corporate Briefing Session 2025 - marketscreener.com
Abbott Laboratories $ABT Shares Sold by Covea Finance - MarketBeat
Avanza Fonder AB Purchases 10,889 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (ABT) News and Stock Outlook on Dec. 25, 2025: FDA Clears Volt PFA, FreeStyle Libre Alert Persists, Exact Sciences Deal Looms - ts2.tech
Abbott Laboratories Stock (ABT) After Hours on Dec. 24, 2025: What to Know Before the Next Market Open on Dec. 26 - ts2.tech
Abbott Laboratories Shrugs Off Tariffs & China Headwinds With 7% Dividend Raise (NYSE:ABT) - Seeking Alpha
Swedbank AB Sells 179,009 Shares of Abbott Laboratories $ABT - MarketBeat
Vontobel Holding Ltd. Sells 1,389,990 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Purchased by IFM Investors Pty Ltd - MarketBeat
GLOBALT Investments LLC GA Boosts Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):